TY - JOUR
T1 - Relapsed and refractory classical Hodgkin lymphoma
T2 - could virotherapy help solve the equation?
AU - Addou, Selma
AU - Sarkozy, Clémentine
AU - Lazarovici, Julien
AU - Champiat, Stéphane
AU - Stamatoullas, Aspasia
AU - Jardin, Fabrice
AU - Ribrag, Vincent
AU - Marabelle, Aurélien
AU - Michot, Jean Marie
N1 - Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outcomes, and new treatment strategies are needed for these young adults. There are several well-documented cases in the medical literature on hematologic cancer remission following natural human viral infections. Therefore, hoping to reproduce these spontaneous tumor regressions, researchers have been investigating various viruses with oncolytic properties. There is a high rationale for using virotherapy in the treatment of Hodgkin lymphoma, in which tumor cells are often infected with the Epstein-Barr virus. Modern viral technologies and current knowledge about the relationship between viruses and cancer could accelerate the discovery of effective viral oncolytic therapies. This article reviews the use of oncolytic viruses as innovative therapies for treating Hodgkin lymphoma.
AB - Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outcomes, and new treatment strategies are needed for these young adults. There are several well-documented cases in the medical literature on hematologic cancer remission following natural human viral infections. Therefore, hoping to reproduce these spontaneous tumor regressions, researchers have been investigating various viruses with oncolytic properties. There is a high rationale for using virotherapy in the treatment of Hodgkin lymphoma, in which tumor cells are often infected with the Epstein-Barr virus. Modern viral technologies and current knowledge about the relationship between viruses and cancer could accelerate the discovery of effective viral oncolytic therapies. This article reviews the use of oncolytic viruses as innovative therapies for treating Hodgkin lymphoma.
KW - Epstein-Barr virus
KW - Hodgkin lymphoma
KW - oncolytic viruses
KW - virotherapy
UR - http://www.scopus.com/inward/record.url?scp=85107678927&partnerID=8YFLogxK
U2 - 10.1080/21645515.2021.1924521
DO - 10.1080/21645515.2021.1924521
M3 - Review article
C2 - 34101538
AN - SCOPUS:85107678927
SN - 2164-5515
VL - 17
SP - 3502
EP - 3510
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 10
ER -